Cancer medicines
Isatuximab
Isatuximab
A CD38-targeting antibody used in myeloma combinations.
Sources checked · Introductory guide
On this page
How it works
It binds CD38 to promote immune-mediated and direct cancer cell death.[3]
Where it is used
Used in selected myeloma combinations with pomalidomide, carfilzomib or other medicines according to prior therapy and transplant eligibility.[1]
Key safety points
Monitor infusion reactions, infection and cytopenias. It can affect compatibility testing; confirm pretreatment tests and disclose use before transfusion.[2]
Questions for your care team
- How are combination medicines, infection prevention and transfusion testing arranged?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Isatuximab-irfc (opens in a new tab)
- MedlinePlus · Isatuximab-irfc (opens in a new tab)
- NCI Drug Dictionary · Isatuximab-irfc (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.